Citations

Mayo Clinic

Showing 10 of 108537 citations.

Medical Malpractice Cases Involving Medical Students
Pollock, Jordan R. , Pollock, Jordan Riley , Shappell, Eric F , Sandefur, Benjamin J. , Moore, M. Lane , Lindor, Rachel A.

Academic Medicine | April 26, 2024 | Volume: 99 | Issue: 10 | Pages: 1108-1116

10.1097/acm.0000000000005746 | PMID 38669133 Get It

Abstract Purpose This study uses a large national legal database to analyze characteristics of malpractice claims involving U.S. medical students. Method The Westlaw database was searched in September 2023 for malpractice cases involving medical students from January 1, 1900, through September 1, 2023. Each case was independently reviewed by 2 authors, abstracting each variable. Categorical data were summarized as frequency of occurrence (i.e., number and percentage), and continuous data were summarized with means, medians, and ranges. All authors independently reviewed the dataset to identify potential themes and codes. Results There were 65 cases that met the inclusion criteria. Reported patient outcomes were death (19, 29%), pain (25, 38%), and disability (36, 55%). The most common specialties involved were emergency medicine (16, 25%), general surgery (14, 22%), and obstetrics and gynecology (13, 20%). The most common primary alleged errors attributed to students related to medical decision-making (30, 46%), procedural complication (24, 37%), and poor communication (11, 17%). Among 23 (35%) cases reporting year of training, 1 (4%) included a second-year student, 13 (57%) included third-year students, and 9 (39%) included fourth-year students. Of the 65 lawsuits, 28 (43%) resulted in a settlement or verdict against the medical student. The total amount paid in these cases was $78,192,612, with a mean (median) of $3,007,408 ($1,050,000) per case. Of these 28 cases, 14 (50%) cited minimal or no physician supervision. Conclusions Medical malpractice claims involving medical students are rare but commonly relate to medical decision-making, procedural complication, and poor communication, with a lack of supervision being frequently cited. These results can be used to guide students and supervising physicians on how to avoid scenarios that may increase vulnerability to medical malpractice lawsuits.
Mapping Novel Frataxin Mitochondrial Networks Through Protein- Protein Interactions
Gnimpiéba, Etienne Z. , Diing, D M, Ailts, Jared, Cucak, Anja, Gakh, Olaksandr, Isaya, Grazia , Vitiello, Seasson Phillips , Wang, Shirley , Pierce, Paul R., Cooper, Alec, Roux, Kyle J. , Roux, Kyle J , Pierce, Paul, Rogers, Lynette Kay , Vitiello, Peter F.

No container title available | April 26, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4259413/v1 | PMID 38746130 Get It

Abstract Friedreich’s Ataxia (FRDA) is a neuromuscular degenerative disorder caused by trinucleotide expansions in the first intron of the frataxin (FXN) gene, resulting in insufficient levels of functional FNX protein. Deficits in FXN involve mitochondrial disruptions including iron-sulfur cluster synthesis and impaired energetics. These studies were to identify unique protein-protein interactions with FXN to better understand its function and design therapeutics. Two complementary approaches were employed, BioID and Co-IP, to identify protein interactions with FXN at the direct binding, indirect binding, and non-proximal levels. Forty-one novel protein interactions were identified by BioID and IP techniques. The FXN protein landscape was further analyzed incorporating both interaction type and functional pathways using a maximum path of 6 proteins with a potential direct interaction between FXN and NFS1. Probing the intersection between FXN-protein landscape and biological pathways associated with FRDA, we identified 41 proteins of interest. Peroxiredoxin 3 (Prdx3) was chosen for further analysis because of its role in mitochondrial oxidative injury. Our data has demonstrated the strengths of employing complementary methods to identify a unique interactome for FXN. Our data provides new insights into FXN function and regulation, a potential direct interaction between FXN and NFS1, and pathway interactions between FXN and Prdx3.
Five-Year Outcomes among U.S. Bronchiectasis and NTM Research Registry Patients
Aksamit, Timothy R. , Locantore, Nicholas , Ali, Juzar , Behrman, Megan, Brunton, Amanda E. , Chalmers, Sarah , Choate, Radmila , Dean, Nathan C. , DiMango, Angela, Fraulino, David , Johnson, Margaret M. , Lapinel, N. , McShane, Pamela J. , Miller, Bruce E. , Naureckas, Edward T. , O’Donnell, Anne E., Olivier, Kenneth N., Prusinowski, Elly, Richards, C. , Rhyne, Gloria, Thomashow, Byron, Tino, Gregory , Tsui, K., Varghese, Sumith Abraham, Warren, Heather E., Winthrop, Kevin , Zha, Beth Shoshanna, Addrizzo-Harris, Doreen , Basavaraj, Ashwin , Brunton, Amanda E , Chalmers, Sarah , Choate, Radmila , Dean, Nathan C , Johnson, Margaret M , Maselli, Diego J , McShane, Pamela J , Miller, Bruce E , O'Donnell, Anne E , Olivier, Kenneth N , Restrepo, Marcos I , Richards, Christopher J , Solomon, George M , Tal-Singer, Ruth , Zha, Beth Shoshanna , Addrizzo‐Harris, Doreen , BARKER, ALAN ROBERT , Metersky, Mark L. , Schmid, Andreas, Tal‐Singer, Ruth , Varghese, Sumith Abraham

American Journal of Respiratory and Critical Care Medicine | April 26, 2024 | Volume: 210 | Issue: 1 | Pages: 108-118

10.1164/rccm.202307-1165oc | PMID 38668710 Get It

Abstract Rationale Nontuberculous mycobacteria (NTM) are prevalent among patients with bronchiectasis. However, the long-term natural history of patients with NTM and bronchiectasis is not well described. Objectives To assess the impact of NTM on 5-year clinical outcomes and mortality in patients with bronchiectasis. Methods Patients in the Bronchiectasis and NTM Research Registry with ⩾5 years of follow-up were eligible. Data were collected for all-cause mortality, lung function, exacerbations, hospitalizations, and disease severity. Outcomes were compared between patients with and without NTM at baseline. Mortality was assessed using Cox proportional hazards models and the log-rank test. Measurements and Main Results In total, 2,634 patients were included: 1,549 (58.8%) with and 1,085 (41.2%) without NTM at baseline. All-cause mortality (95% confidence interval) at Year 5 was 12.1% (10.5%, 13.7%) overall, 12.6% (10.5%, 14.8%) in patients with NTM, and 11.5% (9.0%, 13.9%) in patients without NTM. Independent predictors of 5-year mortality were baseline FEV1 percent predicted, age, hospitalization within 2 years before baseline, body mass index, and sex (all P < 0.01). The probabilities of acquiring NTM or Pseudomonas aeruginosa were approximately 4% and 3% per year, respectively. Spirometry, exacerbations, and hospitalizations were similar, regardless of NTM status, except that annual exacerbations were lower in patients with NTM (P < 0.05). Conclusions Outcomes, including exacerbations, hospitalizations, rate of loss of lung function, and mortality rate, were similar across 5 years in patients with bronchiectasis with or without NTM.
Cytokine CCL9 Mediates Oncogenic KRAS-Induced Pancreatic Acinar-to-Ductal Metaplasia by Promoting Reactive Oxygen Species and Metalloproteinases
Liou, Geou‐Yarh , Byrd, Crystal J., Störz, Peter , Messex, Justin K., Liou, Geou-Yarh

International Journal of Molecular Sciences | April 26, 2024 | Volume: 25 | Issue: 9 | Pages: 4726

10.3390/ijms25094726 | PMID 38731942 Get It

Pancreatic ductal adenocarcinoma (PDAC) can originate from acinar-to-ductal metaplasia (ADM). Pancreatic acini harboring oncogenic Kras mutations are transdifferentiated to a duct-like phenotype that further progresses to become pancreatic intraepithelial neoplasia (PanIN) lesions, giving rise to PDAC. Although ADM formation is frequently observed in KrasG12D transgenic mouse models of PDAC, the exact mechanisms of how oncogenic KrasG12D regulates this process remain an enigma. Herein, we revealed a new downstream target of oncogenic Kras, cytokine CCL9, during ADM formation. Higher levels of CCL9 and its receptors, CCR1 and CCR3, were detected in ADM regions of the pancreas in p48cre:KrasG12D mice and human PDAC patients. Knockdown of CCL9 in KrasG12D-expressed pancreatic acini reduced KrasG12D-induced ADM in a 3D organoid culture system. Moreover, exogenously added recombinant CCL9 and overexpression of CCL9 in primary pancreatic acini induced pancreatic ADM. We also showed that, functioning as a downstream target of KrasG12D, CCL9 promoted pancreatic ADM through upregulation of the intracellular levels of reactive oxygen species (ROS) and metalloproteinases (MMPs), including MMP14, MMP3 and MMP2. Blockade of MMPs via its generic inhibitor GM6001 or knockdown of specific MMP such as MMP14 and MMP3 decreased CCL9-induced pancreatic ADM. In p48cre:KrasG12D transgenic mice, blockade of CCL9 through its specific neutralizing antibody attenuated pancreatic ADM structures and PanIN lesion formation. Furthermore, it also diminished infiltrating macrophages and expression of MMP14, MMP3 and MMP2 in the ADM areas. Altogether, our results provide novel mechanistic insight into how oncogenic Kras enhances pancreatic ADM through its new downstream target molecule, CCL9, to initiate PDAC.
Association of cardiac biomarkers with long-term cardiovascular events in a community cohort
Churchill, Robert , Gochanour, Benjamin R. , Scott, Christopher G. , Vasile, Vlad C. , Rodeheffer, Richard J. , Meeusen, Jeffrey W. , Jaffe, Allan S. , Churchill, Robert A , Scott, Christopher , Vasile, Vlad , Meeusen, Jeffrey W. , Jaffe, Allan S.

Biomarkers | April 26, 2024 | Volume: 29 | Issue: 4 | Pages: 161-170

10.1080/1354750x.2024.2335245 | PMID 38666319 Get It

Visible Peristalsis in a Patient Referred for Chronic Intestinal Pseudo-Obstruction
Yang, David Yi , Cima, Robert R. , Jencks, Kara J. , Lupianez‐Merly, Camille , Camilleri, Michael , Cima, Robert , Jencks, Kara

American Journal of Gastroenterology | April 26, 2024 | Volume: 120 | Issue: 1 | Pages: 26-26

10.14309/ajg.0000000000002838 | PMID 39745300 Get It

Atrial Flutter with Atrial Alternans in a Patient with Cardiac Amyloidosis
Naqvi, Tasneem Z. , Kurt, Merve

No container title available | April 26, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.171412833.34363889/v1 Get It

Mechanical cardiac alternans is usually associated with left ventricular dysfunction. Atrial alternans has been described on invasive assessment of atrial action potentials, however cannot be detected clinically. Herein we report a patient who had transthyretin type cardiac amyloidosis with prior history of recurrent atrial fibrillation requiring ablations as well as ablation for atrial flutter and a recent history of cardioversion for atrial flutter. The patient presented with diastolic heart failure and recurrent atrial flutter and was referred for a TEE guided cardioversion. Mechanical left and right atrial alternans was seen on Doppler interrogation of both atrial appendages with velocities corresponding to the flutter P wave on the ultrasound ECG monitor. The patient was successfully cardioverted with the TEE probe in situ. Post cardioversion TEE showed resumption of normal albeit reduced mechanical atrial function in the left atrium and preserved right atrial function in tissue Doppler imaging. Our case demonstrates the mechanical phenomenon of atrial alternans in both atria on TEE with disappearance of atrial alternans during sinus rhythm suggesting rate related atrial alternans likely related to atrial stiffness from amyloid infiltration and as well as possibly scar formation from prior ablations.
Redefining cerebellar assessment: A comprehensive review of the cerebellum’s cognitive and affective roles and the efficacy of CCAS scales
Alan, Albert, Ennabe, Michelle, Alsarafandi, Muath, Laws, Edward R. , Weinand, Martin , Malik, Noor

Surgical Neurology International | April 26, 2024 | Volume: 15 | Issue: No issue available | Pages: 141

10.25259/sni_226_2024 | PMID 38742008 Get It

Background: Emerging research expands our understanding of the cerebellum beyond motor control to include cognitive, emotional, and autonomic functions. This review examines the cerebellum’s complex role, spotlighting Schmahmann’s syndrome, or cerebellar cognitive affective syndrome (CCAS), which impairs executive functions, language, and spatial processing. It emphasizes advancements in diagnosing CCAS and the imperative of developing superior diagnostic tools for managing cerebellar pathologies effectively. Methods: A comprehensive literature search was performed using databases such as PubMed, OVID Embase, and OVID Medline. Using the keywords “cerebellar cognitive, affective syndrome” and “Schmahmann syndrome,” the search was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines for systemic review, in which the selection process narrowed down an initial set of 54 articles to 12, focusing on the impact of the CCAS scale on diagnosing and understanding Schmahmann’s syndrome. Results: The review’s analysis confirms the cerebellum’s roles in motor and cognitive functions and underscores the CCAS scale as a significant advancement in detecting cerebellar deficits, surpassing traditional assessments such as the mini-mental state examination and Montreal cognitive assessment. Conclusion: This review emphasizes the importance of understanding the cerebellum’s involvement in cognition and emotion and the crucial role of the CCAS scale for identifying cerebellar impairments. It calls for better diagnostic tools to assess CCAS accurately and suggests enhancing the CCAS Scale to reflect cultural and educational diversity. This will improve the diagnosis and treatment of cerebellar disorders, promoting a comprehensive neurological perspective on the cerebellum’s functions.
α‐Synuclein seed amplification assay detects Lewy body co‐pathology in autosomal dominant Alzheimer's disease late in the disease course and dependent on Lewy pathology burden
Xiong, Chengjie , Quadalti, Corinne , Rossi, Marcello , Vöglein, Jonathan , Bernhardt, Alexander , Perrin, Richard J. , Preische, Oliver, Hofmann, Anna, Cairns, Nigel J. , Franklin, Erin , Chrem, Patricio, Berman, Sarah , Chhatwal, Jasmeer P. , Daniels, Alisha , Day, Gregory S. , Ryan, Natalie S. , Goate, Alison , Gordon, Brian A. , Huey, Edward D. , Masters, Colin L. , Morris, John C. , Noble, James M. , Roh, Jee Hoon , Frosch, Matthew P. , Sánchez‐Valle, Raquel , Supnet, Charlene , Network, Dominantly Inherited Alzheimer, Xiong, Chengjie , Parchi, Piero , Gordon, Brian A , Sánchez-Valle, Raquel , Day, Gregory S , Masters, Colin L , Vöglein, Jonathan , Morris, John C , Roh, Jee Hoon , Goate, Alison M , Supnet-Bell, Charlene , Berman, Sarah , Noble, James M , Baiardi, Simone , Iranzo, Alex , Jucker, Mathias , Höglinger, Günter U. , Cruchaga, Carlos , Ibanez, Laura , Karch, Celeste M. , Lee, Jae‐Hong , Llibre‐Guerra, Jorge J. , Lopera, Francisco Javier , Renton, Alan , Keene, C. Dirk , McLean, Catriona , Schofield, Peter R. , Xiong, Chengjie , Giese, Armin , Hansson, Oskar , Bateman, Randall J. , McDade, Eric , Network, Dominantly Inherited Alzheimer

Alzheimer's & Dementia | April 26, 2024 | Volume: 20 | Issue: 6 | Pages: 4351-4365

10.1002/alz.13818 | PMID 38666355 Get It

AbstractINTRODUCTIONAmyloid beta and tau pathology are the hallmarks of sporadic Alzheimer's disease (AD) and autosomal dominant AD (ADAD). However, Lewy body pathology (LBP) is found in ≈ 50% of AD and ADAD brains.METHODSUsing an α‐synuclein seed amplification assay (SAA) in cerebrospinal fluid (CSF) from asymptomatic (n = 26) and symptomatic (n = 27) ADAD mutation carriers, including 12 with known neuropathology, we investigated the timing of occurrence and prevalence of SAA positive reactivity in ADAD in vivo.RESULTSNo asymptomatic participant and only 11% (3/27) of the symptomatic patients tested SAA positive. Neuropathology revealed LBP in 10/12 cases, primarily affecting the amygdala or the olfactory areas. In the latter group, only the individual with diffuse LBP reaching the neocortex showed α‐synuclein seeding activity in CSF in vivo.DISCUSSIONResults suggest that in ADAD LBP occurs later than AD pathology and often as amygdala‐ or olfactory‐predominant LBP, for which CSF α‐synuclein SAA has low sensitivity.Highlights Cerebrospinal fluid (CSF) real‐time quaking‐induced conversion (RT‐QuIC) detects misfolded α‐synuclein in ≈ 10% of symptomatic autosomal dominant Alzheimer's disease (ADAD) patients. CSF RT‐QuIC does not detect α‐synuclein seeding activity in asymptomatic mutation carriers. Lewy body pathology (LBP) in ADAD mainly occurs as olfactory only or amygdala‐predominant variants. LBP develops late in the disease course in ADAD. CSF α‐synuclein RT‐QuIC has low sensitivity for focal, low‐burden LBP.
Feminizing Gender Affirming Breast Surgery: Procedural Outcomes at a Single Academic Institution
Figueroa, Nicole Sanchez, Fahradyan, Vahe , Tran, Nho V. , Martinez‐Jorge, Jorys, Figueroa, Nicole Gabriela Sanchez , Fahradyan, Vahe , Sanchez Figueroa, Nicole Gabriela , Kuruoglu, Doga , Sharaf, Basel

Aesthetic Surgery Journal Open Forum | April 26, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/asjof/ojae032 | PMID 38813116 Get It

Abstract Background Implant-based breast augmentation is a gold standard procedure for transfeminine patients to create a more feminine-appearing chest. In many cases, ancillary procedures are performed simultaneously to achieve an optimal aesthetic result. Objectives To determine the clinical outcomes of patients undergoing feminizing gender-affirming breast surgery in a single academic institution. Methods A retrospective electronic chart review of feminizing gender-affirming breast surgery patients at Mayo Clinic, Rochester from 2017 to 2022 was conducted. Patients demographics and surgical outcomes were gathered. A survival analysis was performed to obtain the time-to-event complication rate. Results Over 5 years, 46 patients (92 breasts) were included. The mean age was 39 years (SD ±15), and most had an above-normal Body Mass Index (58.7%). Thirty (65%) had previous gender-affirming surgeries. The mean implant volume was 289 ml (SD ±95; 140 - 520). Most implants were placed in a subglandular plane (81%) with an inframammary fold incision (91.3%). All implants used were smooth round cohesive silicone gel implants. Ancillary procedures were performed in thirty-two patients (69.57%). Eight patients presented complications (4 major vs 4 minor) in a median postoperative follow-up of 372 vs 392 days; at 1-month follow-up, the probability of a complication to have occurred is 2.17% (95% CI: 0–6.3%) vs 5% (95% CI: 0–11.5%) and at 1 year is 10.21% (95% CI: 0–20.9%) vs 12.5% (95% CI: 0–23.4%) ​which remain the same up to 4 years. Conclusions Breast augmentation with implants is a safe procedure to achieve feminization of the breast with a low rate of complications.